HHE Haematology supplement 2018 | Page 6

Empowering
personalized
treatment decisions
When every patient is different and every tumor is unique,
the therascreen PITX2 RGQ PCR Kit can provide the genomic
information needed to personalize breast cancer care.
The first clinically validated CE-IVD DNA methylation assay
to predict response to anthracycline-based chemotherapy in
certain high-risk breast cancer patients.
Contact QIAGEN today to discover more about molecular
detection technologies. Ordering www.qiagen.com/shop
The therascreen PITX2 RGQ PCR Kit is intended for in vitro diagnostic use in Europe.
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN
handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com
or can be requested from QIAGEN Technical Services at your local distributor.
Trademarks: QIAGEN ® , Sample to Insight ® , therascreen ® (QIAGEN Group); Endopredict ® (Sividon
Diagnostics). Rotor-Gene ® (QIAGEN Group). Registered names, trademarks, etc. used in this
document, even when not specifically marked as such, are not to be considered unprotected by law.
PROM-12523-001 06/2018 © 2018 QIAGEN, all rights reserved.
Sample to Insight